Court approves Abbott settlement for wrongly marketing Depakote

The pharmaceutical company will pay $1.5 billion for marketing the drug for non-approved uses.

The Associated Press/Washington Post: Federal Court In Va. Approved $1.5B Abbott Laboratories Settlement Over Depakote
A federal court in Virginia on Tuesday approved a settlement in which Abbott Laboratories agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration ... Depakote is an anti-seizure and mood-stabilizing drug prescribed for bipolar disorder (10/2).

The Wall Street Journal: Court Sentences Abbott For Off-Label Promotion Of Antiseizure Drug
Abbott was ordered to pay a criminal fine of $500 million, forfeit another $198.5 million, and pay $1.5 million to the Virginia Medicaid Fraud Control Unit for marketing the drug for patients with dementia and schizophrenia. The drug manufacturer will also be subject to a five-year term of probation (Jones, 10/2).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post